Fungal lung infections

Fungal lung infections occur when pathogenic fungi colonize or invade the respiratory tract, leading to a spectrum of diseases ranging from mild, self-limiting conditions to life-threatening invasive infections. Common pathogens include Aspergillus, Histoplasma, Cryptococcus, and Candida species. These infections are more prevalent in immunocompromised patients, such as those with HIV, malignancies, or post-transplant status, but can also affect otherwise healthy individuals exposed to high fungal loads. Clinical manifestations vary depending on the host immune response and the fungal species involved, including persistent cough, fever, chest pain, hemoptysis, and shortness of breath. Early diagnosis is challenging due to overlapping symptoms with bacterial or viral infections, necessitating a combination of imaging, microbiological cultures, and serologic or molecular testing. Accurate identification of the causative organism is crucial for directing appropriate therapy and improving outcomes.

Management of fungal lung infections requires a tailored approach based on pathogen, disease severity, and host factors. Antifungal therapy, including agents such as azoles, echinocandins, or amphotericin B, forms the backbone of treatment, often for prolonged durations to ensure eradication. Supportive care, including oxygen supplementation and respiratory physiotherapy, is important for symptom relief and pulmonary recovery. In select cases, surgical resection may be required for localized or complicated lesions. Prevention strategies, such as minimizing environmental exposures in high-risk patients, prophylactic antifungal use in immunocompromised populations, and monitoring for early signs of infection, significantly reduce morbidity. Multidisciplinary collaboration among pulmonologists, infectious disease specialists, and radiologists ensures individualized care, timely interventions, and improved survival.